Technology
Health
Biotechnology

Idera Pharmaceuticals

$2.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-9.33%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell IDRA and other stocks, options, ETFs, and crypto commission-free!

About

Idera Pharmaceuticals, Inc. Common Stock, also called Idera Pharmaceuticals, is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. Read More The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.

Employees
36
Headquarters
Exton, Pennsylvania
Founded
1989
Market Cap
73.95M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
325.58K
High Today
$2.98
Low Today
$2.66
Open Price
$2.98
Volume
316.62K
52 Week High
$17.12
52 Week Low
$2.25

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
US
North America

News

Simply Wall StMar 7

Easy Come, Easy Go: How Idera Pharmaceuticals Shareholders Got Unlucky And Saw 94% Of Their Cash Evaporate

Long term investing is the way to go, but that doesn’t mean you should hold every stock forever. We really hate to see fellow investors lose their hard-earned money. Spare a thought for those who held Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for five whole years – as the share price tanked 94%. And we doubt long term believers are the only worried holders, since the stock price has declined 82% over the last twelve months. Shareholders have had an even rougher run lately, with the share price down 54% in t...

79
MarketBeatFeb 23

Stock Price, News, & Analysis for Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipi...

31

Earnings

-$0.59
-$0.42
-$0.25
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.